
ICMR has partnered with Bharat Biotech lnternational Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID Vaccine) and its clinical trials were approved by DCGI by end of June.
Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

ICMR has partnered with Bharat Biotech lnternational Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID Vaccine) and its clinical trials were approved by DCGI by end of June.

Sun Pharma and includes its subsidiaries and/or associate companies) announced that one of its wholly-owned subsidiaries has received approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for ILUMYA (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies. Japan has approximately 430,000 people currently suffering from psoriasis.

Drug Controller General of India (DCGI) has given approval for human clinical trials of COVAXIN, the first potential COVID-19 Vaccine developed in India. The potential vaccine has been developed by Hyderabad-based Bharat Biotech, in association with Indian Council for Medical Research (ICMR). Human Trials for Phase I and Phase II are scheduled to start across the country from next month.

Scientists from the Institute of Nano Science & Technology (INST), Mohali, an autonomous institute of the Department of Science and Technology Government of India, have synthesized a novel inorganic-organic hybrid compound that can inhibit breast, lung, and liver cancer cells, opening up new possibilities for metallodrugs.
Hindustan Unilever Limited (HUL) announced that it has completed the acquisition of intimate hygiene brand VWash from Glenmark Pharmaceuticals Ltd. This acquisition was announced on March 23, 2020 and was subject to certain closing conditions, which have now been fulfilled.

Sharing of Health Data of Public and Pvt Hospitals critical to development of Digital Health in India and it can go a long way in forecasting and managing Pandemics: Mahendra Singh Expert Member for Digital Health, WHO Global Digital Health, WHO Geneva

The U.S. Food and Drug Administration approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy. It is often characterized by severe and unrelenting seizures despite medical treatment.

TLeishmaniasis is a neglected tropical disease affecting almost 100 countries including India. It is caused by a parasite called Leishmania, which is transmitted through the bite of sand flies.

AYUSH Industry has been considered as an Essential Industry during Covid times and hence ready to be integrated with Public Health Delivery and Innovation and the AYUSH Standard and Premium marks are the way ahead for Global reach said Dr. Manoj Nesari, Advisor, Ministry of AYUSH, Govt. of India